Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15034514 | 0.96 | GRM5 (0.49) | GRM5SLC6A7MAPTMEN1KMT2A | |
| SCHEMBL15034524 | 0.91 | L3MBTL1 (0.49) | GRM5SMN1; SMN2SLC6A7MAPTTP53 | |
| SCHEMBL15034541 | 0.90 | GRM5 (0.64) | GRM5SLC6A7 | |
| SCHEMBL15034519 | 0.89 | KDM4E (0.57) | GRM5KDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL15034536 | 0.89 | GRM5 (0.54) | GRM5KDM4ESLC6A7LMNAMEN1 | |
| SCHEMBL15034517 | 0.86 | GRM5 (0.58) | GRM5KDM4ESMN1; SMN2SLC6A7MAPT | |
| SCHEMBL15034513 | 0.84 | GRM5 (0.55) | GRM5KDM4ESMN1; SMN2MAPTLMNA | |
| SCHEMBL15034518 | 0.82 | GRM5 (0.53) | GRM5KDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL15034521 | 0.81 | GRM5 (0.48) | GRM5SMN1; SMN2MAPTTP53LMNA | |
| SCHEMBL15034520 | 0.81 | LMNA (0.42) | GRM5SMN1; SMN2MAPTTP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937176-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8937176-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-20130158038-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158038-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158038-A1 | NOVEL COMPOUNDS | GRM5, GRIN1, GRM1 | GRM5 1/4885KDM4E 1915/4885SMN1; SMN2 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.